These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 18061885

  • 1. Pharmacogenetics of EGFR and VEGF inhibition.
    Pander J, Gelderblom H, Guchelaar HJ.
    Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885
    [Abstract] [Full Text] [Related]

  • 2. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J.
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA, Lynch TJ.
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [Abstract] [Full Text] [Related]

  • 12. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T.
    Clin Cancer Res; 2008 Feb 01; 14(3):840-6. PubMed ID: 18245547
    [Abstract] [Full Text] [Related]

  • 13. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
    Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C.
    Eur J Cancer; 2009 Sep 01; 45 Suppl 1():309-17. PubMed ID: 19775627
    [No Abstract] [Full Text] [Related]

  • 14. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J.
    Clin Colorectal Cancer; 2008 Dec 01; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanisms of cutaneous toxicities to EGFR inhibitors.
    Lacouture ME.
    Nat Rev Cancer; 2006 Oct 01; 6(10):803-12. PubMed ID: 16990857
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New therapeutic agents targeting the epidermal growth factor receptor.
    Baselga J.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):54S-9S. PubMed ID: 11060328
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.